Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Change in Cash (2021 - 2025)

Historic Change in Cash for Krystal Biotech (KRYS) over the last 5 years, with Q4 2025 value amounting to $103.7 million.

  • Krystal Biotech's Change in Cash rose 45634.51% to $103.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $151.4 million, marking a year-over-year increase of 122485.33%. This contributed to the annual value of $151.4 million for FY2025, which is 122485.33% up from last year.
  • As of Q4 2025, Krystal Biotech's Change in Cash stood at $103.7 million, which was up 45634.51% from $38.8 million recorded in Q3 2025.
  • In the past 5 years, Krystal Biotech's Change in Cash registered a high of $135.1 million during Q2 2023, and its lowest value of -$72.6 million during Q2 2021.
  • Over the past 5 years, Krystal Biotech's median Change in Cash value was -$14.1 million (recorded in 2023), while the average stood at $11.4 million.
  • Examining YoY changes over the last 5 years, Krystal Biotech's Change in Cash showed a top increase of 45634.51% in 2025 and a maximum decrease of 542374.63% in 2025.
  • Krystal Biotech's Change in Cash (Quarter) stood at $54.6 million in 2021, then tumbled by 144.86% to -$24.5 million in 2022, then skyrocketed by 39.15% to -$14.9 million in 2023, then crashed by 95.14% to -$29.1 million in 2024, then soared by 456.35% to $103.7 million in 2025.
  • Its Change in Cash was $103.7 million in Q4 2025, compared to $38.8 million in Q3 2025 and $45.1 million in Q2 2025.